Coral Laboratories share news and announcements
BSE: 524506Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹506.95.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹177 Cr2,551st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 20 Oct 2026
- 9.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 Sep 2026
- 0.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.40%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 20 Oct 2026
- 9.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 20 Oct 2026
- 7.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 Sep 2026
- 0.02
- Volume, BSEVolume. Shares traded on the last trading day.
- 2,855
Coral Laboratories share news and announcements
720 announcements, routine notices left out, newest first. Page 4 of 15.
Jan 2024
6 Jan · Management
Nov 2023
24 Nov · Announcement under Regulation 30 (LODR)-Change in Registered Office Address
9 Nov · Disclosure Under Reg 23(9) Of SEBI (LODR) Regulations, 2015
2 Nov · Board meeting
Meeting on 9 Nov 2023: quarterly results
Sep 2023
20 Sep · Board meeting
Meeting on 26 Sep 2023
Aug 2023
11 Aug · Alteration Of Memorandum Of Association (MOA) Of The Company
7 Aug · Board meeting
Meeting on 12 Aug 2023: quarterly results
Jul 2023
11 Jul · Announcement under Regulation 30 (LODR)-Meeting Updates
4 Jul · Board meeting
Meeting on 11 Jul 2023
May 2023
23 May · Disclosure Under Reg 23(9) Of SEBI (LODR) Regulations, 2015
16 May · Board meeting
Meeting on 23 May 2023: audited results
Apr 2023
13 Apr · Compliance Certificate From PCS As Per Regulation 40(9) And 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
6 Apr · Compliance Certificate Under Reg 7(3) Of SEBI (LODR) Regulations, 2015 For The Year Ended March 31, 2023.
Feb 2023
7 Feb · Board meeting
Meeting on 14 Feb 2023: quarterly results
Jan 2023
Nov 2022
18 Nov · Disclosure Under Reg 23(9) Of SEBI (LODR) Regulations 2015 For Half Year Ended September 30, 2022
4 Nov · Board meeting
Meeting on 11 Nov 2022: quarterly results
Oct 2022
12 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Sep 2022